Document Detail


Recurrence and prognostic factors in borderline ovarian tumors.
MedLine Citation:
PMID:  16009407     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of this study was to evaluate the survival estimates and clinico-pathological variables in patients treated for borderline ovarian tumors. METHODS: The patients treated for borderline ovarian tumors were evaluated retrospectively. Data were obtained from hospital records and special gynecologic oncology forms. RESULTS: Overall, 100 patients were evaluated. The mean age at the time of diagnosis was 41.7 (range, 19-84). Seventy one (71%) patients underwent surgical staging including 49 (49%) of them with comprehensive surgical staging, 22 (22%) with fertility-sparing surgery. Only 30 (30%) patients were unstaged. The histopathological diagnosis was serous, mucinous, and the other types of borderline ovarian tumor in 54 (54%), 39 (39%), and 7 (7%) of the patients, respectively. Seventy patients had stage IA (70%), 10 had stage IB (10%), 9 had stage IC (9%), 3 had stage IIIA (3%), and 8 had stage IIIC (8%) disease. The stage of only four patients in which disease confined to ovary was upgraded as stage IIIC following surgical staging procedure. The recurrence rate was found 3% (3). The overall disease-free survival rates of BOT in surgically staged (comprehensive, fertility-sparing surgery) and unstaged patients were 97.92%, 95.00%, and 96.30%, respectively. But, the overall tumor-free survival was significantly found to be decreased in cases of young age (<30 years old), performing fertility-sparing surgery and presence of micropapillary architecture or peritoneal implants. Overall survival rates of BOT in surgically staged (comprehensive, fertility-sparing surgery) and unstaged patients were 97.9%, and 100% and 100%, respectively. CONCLUSION: Low malignant potential ovarian tumors have excellent survival, and the patients can be treated safely by conservative surgery.
Authors:
Ali Ayhan; Emine Seda Guvendag Guven; Suleyman Guven; Turkan Kucukali
Related Documents :
20482487 - Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcin...
21252667 - Anaplastic thyroid carcinoma: palliation or treatment?
6445047 - Second-look laparoscopy prior to proposed second-look laparotomy.
21415957 - Medical treatment of hepatocellular carcinoma.
18717757 - Natural history of hepatitis b virus-related cirrhotic patients hospitalized to control...
2015547 - Chemotherapy and radiation therapy for anal carcinoma. survival and late morbidity.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Gynecologic oncology     Volume:  98     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-22     Completed Date:  2005-11-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  439-45     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University Faculty of Medicine, Mahmut Esat Bozkurt Caddesi No: 69/2 ONCEBECI, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Ovarian Neoplasms / pathology*,  surgery*
Retrospective Studies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metastatic testicular seminoma to the prostate.
Next Document:  Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.